Table 2. Summary of patient characteristics in the chemotherapy costing analysis.
| N | Mean (standard deviation) | |
|---|---|---|
| Age (years) | 106 | 53.2 (11.3) |
| Height (cm) | 106 | 161.4 (7.4) |
| Weight (kg) | 106 | 64.9 (13.4) |
| Surface area (m2) | 106 | 1.7 (0.2) |
| Working status (%) | 92 | |
| Working | 62.1 | |
| Not working | 10.8 | |
| Retired | 27.1 | |
| Tumor stage (%) | 100 | |
| 1 | 50.0 | |
| 2 | 50.0 | |
| TNM staging (%) | 106 | |
| T1n0 | 49.0 | |
| T2n0 | 47.1 | |
| T3n0 | 3.7 | |
| HER2 negative (%) | 106 | 100 |
| ER positive (%) | 106 | 0 |
| PR positive (%) | 106 | 83.1 |
| Chemotherapy cycles under protocol (%) | 106 | |
| Docetaxel | 27.6 | |
| Docetaxel + C | 13.5 | |
| Docetaxel + C + E | 3.1 | |
| Doxorubicine + C | 2.6 | |
| Epirubicine | 0.2 | |
| Epirubicine + C | 3.3 | |
| Epirubicine + C + 5FU | 47.5 | |
| Epirubicine + 5FU | 0.2 | |
| Paclitaxel | 1.7 | |
| Paclitaxel + C | 0.3 |
C, cyclophosphamide; E, epirubicin; 5FU, fluorouracil; HER, human epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone receptor.